Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 35Gastrointestinal 28Thoracic 25Other hematologic neoplasm 25Genitourinary 21Other solid neoplasm 17Head & Neck 16Gynecologic 13Tumor-Agnostic 10Lymphoid 9Dermatologic 7CNS 6Plasma cell 5Sarcoma 3Myeloid 3Other 2Other neoplasm 1Endocrine 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Practice Guidelines as Topic × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡